BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded BioCryst Pharmaceuticals to “strong-buy” from “hold.” Other analysts remain generally positive, with eight Buy ratings and four Holds, an average “Moderate Buy” rating, and a consensus price target of $20.60.
• BioCryst reported quarterly EPS of $0.30, beating the $0.15 consensus estimate, while revenue of $218.25 million exceeded expectations and increased 33.6% year over year.
• The stock opened at $9.38, with a market capitalization of approximately $2.38 billion and a 12-month trading range of $6.00 to $11.22; institutional investors own 85.88% of shares.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Saturday.

Several other equities analysts have also recently issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research report on Thursday. JPMorgan Chase & Co. began coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a "neutral" rating and a $12.00 price objective on the stock. Wedbush decreased their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Cantor Fitzgerald raised their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $20.60.

BioCryst Pharmaceuticals Trading Up 0.9%

BioCryst Pharmaceuticals stock opened at $9.38 on Friday. The stock has a 50-day moving average price of $9.33 and a two-hundred day moving average price of $8.71. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.22. The company has a market capitalization of $2.38 billion, a PE ratio of -6.25 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm's revenue was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 earnings per share. As a group, analysts predict that BioCryst Pharmaceuticals will post -2.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Larson Financial Group LLC raised its stake in BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company's stock worth $28,000 after buying an additional 3,267 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at $101,000. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals during the third quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 2,115 shares during the period. Finally, Hilltop Holdings Inc. acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth about $98,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source